ORALLY ADMINISTRABLE LIPOSOMALLY ENCAPSULATED REDUCED GLUTATHIONE, WITH N-O ENHANCING COMPOUNDS FOR REVERSAL AND PREVENTION OF OXIDATION OF CHOLESTEROL AND OF LOW DENSITY LIPOPROTEIN
The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.
1 - 22 . (canceled)
23 . A pharmaceutical composition for treatment of vascular disease, in a mammalian patient, comprising:
reduced glutathione in a liposomal formulation capable of administration intravenously, orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and
a compound selected from the group of materials that increase nitric oxide production.
24 . The pharmaceutical composition according to claim 23 , further comprising:
said compound selected from the group of materials that increase nitric oxide production being arginine.
25 . The pharmaceutical composition according to claim 23 , further comprising:
said compound selected from the group of materials that increase nitric oxide production being lysine.
26 . The pharmaceutical composition according to any one of claims 23 - 25 , further comprising:
selenium.